![Thomas Jung](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Jung
Corporate Officer/Principal en University of Göttingen .
Perfil
Thomas Jung is currently an Associate Professor at the University of Göttingen.
Previously, he worked as a Director at AIMM Therapeutics BV, and as the Head of European Translational Medicine at Novartis AG and Novartis Institutes for Biomedical Research, Inc. He also served as the Chief Medical Officer at Cell Medica Switzerland AG and as the Chief Development Officer at Auris Medical Holding AG.
Dr. Jung holds a doctorate degree from the Philipps University of Marburg.
Cargos activos de Thomas Jung
Empresas | Cargo | Inicio |
---|---|---|
University of Göttingen | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Thomas Jung.
Empresas | Cargo | Fin |
---|---|---|
Auris Medical Holding AG /Old/
![]() Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland. | Corporate Officer/Principal | - |
AIMM Therapeutics BV
![]() AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Director/Miembro de la Junta | - |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
NOVARTIS AG | Corporate Officer/Principal | - |
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Director Técnico/Científico/I+D | - |
Formación de Thomas Jung.
Philipps University of Marburg | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NOVARTIS AG | Health Technology |
Empresas privadas | 4 |
---|---|
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
AIMM Therapeutics BV
![]() AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Auris Medical Holding AG /Old/
![]() Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Jung